{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:51:39Z","timestamp":1790268699930,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.pharma.2024.05.006","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T06:26:00Z","timestamp":1717136760000},"page":"1034-1045","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Validated LC\/MS method for simultaneous determination of elbasvir and grazoprevir in human plasma"],"prefix":"10.1016","volume":"82","author":[{"given":"Aymen","family":"Labidi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafika","family":"Bensghaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Jebali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7821-2933","authenticated-orcid":false,"given":"Latifa","family":"Latrous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2024.05.006_bib0220","series-title":"Strategies of detection and challenges for hepatitis C infectious disease. Biosens. Emerg. Re-Emerg. Infect. Dis","first-page":"303","author":"Moharana","year":"2022"},{"key":"10.1016\/j.pharma.2024.05.006_bib0225","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.3748\/wjg.v27.i13.1267","article-title":"Metabolic complications of hepatitis C virus infection","volume":"27","author":"Chaudhari","year":"2021","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.pharma.2024.05.006_bib0230","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02437-21","article-title":"Three-stage pooled plasma hepatitis C virus RNA testing for the identification of Acute HCV infections in at-risk populations","volume":"10","author":"Sun","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.pharma.2024.05.006_bib0235","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1111\/jvh.13574","article-title":"Global cascade of care for chronic hepatitis C virus infection: a systematic review and meta-analysis","volume":"28","author":"Yousafzai","year":"2021","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.pharma.2024.05.006_bib0240","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1002\/hep4.2012","article-title":"Iron overload disorders","volume":"6","author":"Hsu","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.pharma.2024.05.006_bib0245","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.4254\/wjh.v13.i11.1727","article-title":"Cystic fibrosis-associated liver disease in children","volume":"13","author":"Valamparampil","year":"2021","journal-title":"World J Hepatol"},{"key":"10.1016\/j.pharma.2024.05.006_bib0250","doi-asserted-by":"crossref","first-page":"e2354","DOI":"10.1002\/rmv.2354","article-title":"Global and regional circulation trends of norovirus genotypes and recombinants, 1995\u20132019: a comprehensive review of sequences from public databases","volume":"32","author":"Kendra","year":"2022","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.pharma.2024.05.006_bib0255","doi-asserted-by":"crossref","first-page":"308","DOI":"10.47191\/ijmscrs\/v2-i5-04","article-title":"Risk factors for treatment failure with oral antivirals in HCV","volume":"02","author":"Malhotra","year":"2022","journal-title":"Int J Med Sci Clin Res Stud"},{"key":"10.1016\/j.pharma.2024.05.006_bib0260","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1021\/acs.chemrev.0c00648","article-title":"Drug design strategies to avoid resistance in direct-acting antivirals and beyond","volume":"121","author":"Matthew","year":"2021","journal-title":"Chem Rev"},{"key":"10.1016\/j.pharma.2024.05.006_bib0265","first-page":"100237","article-title":"Pangenotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection: a systematic literature review and meta-analysis","volume":"18","author":"Zoratti","year":"2020","journal-title":"EClin Med"},{"key":"10.1016\/j.pharma.2024.05.006_bib0270","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.3390\/v13112249","article-title":"A review on extrahepatic manifestations of chronic hepatitis C virus infection and the impact of direct-acting antiviral therapy","volume":"13","author":"Mazzaro","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.pharma.2024.05.006_bib0275","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1093\/cid\/ciz696","article-title":"Efficacy of direct-acting antivirals for chronic hepatitis C virus infection in people who inject drugs or receive opioid substitution therapy: a systematic review and meta-analysis","volume":"70","author":"Graf","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pharma.2024.05.006_bib0280","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s42250-021-00253-9","article-title":"RP-HPLC stability indicating method development and validation for simultaneous determination of grazoprevir and elbasvir","volume":"4","author":"Labidi","year":"2021","journal-title":"Chem Afr"},{"key":"10.1016\/j.pharma.2024.05.006_bib0285","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s40265-017-0739-8","article-title":"Elbasvir\/grazoprevir: a review in chronic HCV genotypes 1 and 4","volume":"77","author":"Al-Salama","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.pharma.2024.05.006_bib0290","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1093\/cid\/ciy547","article-title":"High cure rates with grazoprevir-elbasvir with or without ribavirin guided by genotypic resistance testing among human immunodeficiency virus\/hepatitis C virus\u2013coinfected men who have sex with men","volume":"68","author":"Braun","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pharma.2024.05.006_bib0295","unstructured":"Perri GD, Cariti G. Drug\u2013drug interactions in anti-HCV therapy: a comparison among options available in Italy. n.d.: 12."},{"key":"10.1016\/j.pharma.2024.05.006_bib0300","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41586-022-05522-2","article-title":"The WHO estimates of excess mortality associated with the COVID-19 pandemic","volume":"613","author":"Msemburi","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.pharma.2024.05.006_bib0305","first-page":"195","article-title":"The effects of the COVID-19 pandemic on community respiratory virus activity","volume":"21","author":"Chow","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.pharma.2024.05.006_bib0310","doi-asserted-by":"crossref","first-page":"1009393","DOI":"10.3389\/fpubh.2022.1009393","article-title":"COVID-19 outbreak: impact on global economy","volume":"10","author":"Naseer","year":"2023","journal-title":"Front Public Health"},{"key":"10.1016\/j.pharma.2024.05.006_bib0315","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2105\/AJPH.2022.306839","article-title":"The COVID-19 pandemic, socioeconomic effects, and intimate partner violence against women: a population-based cohort study in 2020, Iran","volume":"113","author":"Fereidooni","year":"2023","journal-title":"Am J Public Health"},{"key":"10.1016\/j.pharma.2024.05.006_bib0320","doi-asserted-by":"crossref","first-page":"7307","DOI":"10.1038\/s41598-021-86712-2","article-title":"Computational drug repurposing study elucidating simultaneous inhibition of entry and replication of novel corona virus by Grazoprevir","volume":"11","author":"Behera","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.pharma.2024.05.006_bib0325","doi-asserted-by":"crossref","first-page":"173701","DOI":"10.1016\/j.ejphar.2020.173701","article-title":"In silico identification of strong binders of the SARS-CoV-2 receptor-binding domain","volume":"890","author":"Behloul","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharma.2024.05.006_bib0330","first-page":"S109","article-title":"Molecular docking and dynamics simulations reveal the potential of anti-HCV drugs to inhibit COVID-19 main protease","volume":"27","author":"Al-Karmalawy","year":"2021","journal-title":"Pharm Sci"},{"key":"10.1016\/j.pharma.2024.05.006_bib0335","doi-asserted-by":"crossref","first-page":"711","DOI":"10.4155\/bio-2021-0039","article-title":"Quantification of abemaciclib and metabolites: evolution of bioanalytical methods supporting a novel oncolytic agent","volume":"13","author":"Wickremsinhe","year":"2021","journal-title":"Bioanalysis"},{"key":"10.1016\/j.pharma.2024.05.006_bib0340","doi-asserted-by":"crossref","first-page":"119505","DOI":"10.1016\/j.saa.2021.119505","article-title":"Simultaneous spectrophotometric quantitative analysis of elbasvir and grazoprevir using assisted chemometric models","volume":"252","author":"Zeid","year":"2021","journal-title":"Spectrochim Acta A Mol Biomol Spectrosc"},{"key":"10.1016\/j.pharma.2024.05.006_bib0345","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.saa.2017.08.026","article-title":"Application of different spectrophotometric methods for simultaneous determination of elbasvir and grazoprevir in pharmaceutical preparation","volume":"189","author":"Attia","year":"2018","journal-title":"Spectrochim Acta A Mol Biomol Spectrosc"},{"key":"10.1016\/j.pharma.2024.05.006_bib0350","doi-asserted-by":"crossref","first-page":"119157","DOI":"10.1016\/j.saa.2020.119157","article-title":"Simultaneous determination of elbasvir and grazoprevir in their pharmaceutical formulation by synchronous fluorescence spectroscopy coupled to dual wavelength method","volume":"248","author":"Attia","year":"2021","journal-title":"Spectrochim Acta A Mol Biomol Spectrosc"},{"key":"10.1016\/j.pharma.2024.05.006_bib0355","first-page":"7","article-title":"Recent development and validation of RP-HPLC method for simultaneous estimation of grazoprevir and elbasvir in bulk and pharmaceutical dosage form","volume":"3","author":"Padmavathi","year":"2021","journal-title":"Technol Innov Pharm Res"},{"key":"10.1016\/j.pharma.2024.05.006_bib0360","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1080\/10408347.2021.1923456","article-title":"A review on analytical strategies for the assessment of recently approved direct acting antiviral drugs","volume":"52","author":"Aboras","year":"2022","journal-title":"Crit Rev Anal Chem"},{"key":"10.1016\/j.pharma.2024.05.006_bib0365","series-title":"RP-HPLC method development and validation for simultaneous estimation of grazoprevir and elbasvir in bulk and its dosage form with stress studies","author":"Arunkumar","year":"2019"},{"key":"10.1016\/j.pharma.2024.05.006_bib0370","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s42250-021-00253-9","article-title":"RP-HPLC stability indicating method development and validation for simultaneous determination of grazoprevir and elbasvir","volume":"4","author":"Labidi","year":"2021","journal-title":"Chem Afr"},{"key":"10.1016\/j.pharma.2024.05.006_bib0375","first-page":"272","article-title":"LC-MS\/MS method development and validation for simultaneous quantification of elbasvir and grazoprevir in human plasma","volume":"5","author":"Shyam","year":"2018","journal-title":"Eur J Biomed"},{"key":"10.1016\/j.pharma.2024.05.006_bib0380","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jchromb.2019.01.024","article-title":"Quantification of second generation direct-acting antivirals daclatasvir, elbasvir, grazoprevir, ledipasvir, simeprevir, sofosbuvir and velpatasvir in human plasma by UPLC-MS\/MS","volume":"1110","author":"van Seyen","year":"2019","journal-title":"J Chromatogr B"},{"key":"10.1016\/j.pharma.2024.05.006_bib0385","doi-asserted-by":"crossref","first-page":"112964","DOI":"10.1016\/j.jpba.2019.112964","article-title":"Simultaneous determination of elbasvir and grazoprevir in fixed-dose combination and mass spectral characterization of each degradation product by UHPLC-ESI-QTOF-MS\/MS","volume":"178","author":"Chen","year":"2020","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.pharma.2024.05.006_bib0390","doi-asserted-by":"crossref","first-page":"106512","DOI":"10.1016\/j.microc.2021.106512","article-title":"Cost-effective green chromatographic method for the simultaneous determination of four commonly used direct-acting antiviral drugs in plasma and various pharmaceutical formulations","volume":"168","author":"El-Yazbi","year":"2021","journal-title":"Microchem J"},{"key":"10.1016\/j.pharma.2024.05.006_bib0395","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/jssc.202100452","article-title":"Homogeneous liquid\u2013liquid extraction as an alternative sample preparation technique for biomedical analysis","volume":"45","author":"Hammad","year":"2022","journal-title":"J Sep Sci"},{"key":"10.1016\/j.pharma.2024.05.006_bib0400","doi-asserted-by":"crossref","first-page":"6761","DOI":"10.3390\/molecules27196761","article-title":"Simultaneous quantification of opioids in blood and urine by gas chromatography-mass spectrometer with modified dispersive solid-phase extraction technique","volume":"27","author":"Yasien","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.pharma.2024.05.006_bib0405","doi-asserted-by":"crossref","first-page":"67","DOI":"10.17145\/jab.18.010","article-title":"Bioanalytical method development and validation: from the USFDA 2001 to the USFDA 2018 guidance for industry","volume":"4","author":"Meesters","year":"2018","journal-title":"J Appl Bioanal"},{"key":"10.1016\/j.pharma.2024.05.006_bib0410","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s41742-017-0054-y","article-title":"A combination of factorial design, off-line SPE and GC\u2013MS method for quantifying seven endocrine disrupting compounds in water","volume":"11","author":"Ben Sghaier","year":"2017","journal-title":"Int J Environ Res"},{"key":"10.1016\/j.pharma.2024.05.006_bib0415","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s42250-022-00344-1","article-title":"Optimization and validation in liquid chromatography using design of experiments","volume":"5","author":"Latrous","year":"2022","journal-title":"Chem Afr"},{"key":"10.1016\/j.pharma.2024.05.006_bib0420","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/chromsci\/bmz076","article-title":"Chemometrically assisted development of ultra-high-performance liquid chromatography method for the simultaneous quantification of sofosbuvir, daclatasvir and ledipasvir in pharmaceutical dosage forms","volume":"57","author":"Labidi","year":"2019","journal-title":"J Chromatogr Sci"},{"key":"10.1016\/j.pharma.2024.05.006_bib0425","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3897\/pharmacia.69.e83705","article-title":"Determination of amino acids of plants from Angelica L. genus by HPLCmethod","volume":"69","author":"Budniak","year":"2022","journal-title":"Pharmacia"},{"key":"10.1016\/j.pharma.2024.05.006_bib0430","doi-asserted-by":"crossref","first-page":"128173","DOI":"10.1016\/j.foodchem.2020.128173","article-title":"Development of an analytical method for the quantitative determination of multi-class nutrients in different food matrices by solid-phase extraction and liquid chromatography-tandem mass spectrometry using design of experiments","volume":"341","author":"Arvapally","year":"2021","journal-title":"Food Chem"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450924000890?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450924000890?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T17:48:01Z","timestamp":1729705681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450924000890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0003450924000890"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2024.05.006","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Validated LC\/MS method for simultaneous determination of elbasvir and grazoprevir in human plasma","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2024.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}